MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Provides a general description of the business conducted by this company. The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.
The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.
Key Earnings Data
The technique has proven to be very useful for finding positive surprises. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
We’d like to share more about how we work and what drives our day-to-day business. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. https://1investing.in/ 4 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Leap Therapeutics in the last year. The consensus among Wall Street research analysts is that investors should “buy” LPTX shares. According to the issued ratings of 4 analysts in the last year, the consensus rating for Leap Therapeutics stock is Buy based on the current 4 buy ratings for LPTX.
4 Wall Street research analysts have issued 1-year target prices for Leap Therapeutics’ shares. On average, they anticipate the company’s stock price to reach $18.80 in the next twelve months. This suggests a possible upside of 1,039.3% from the stock’s current price. View analysts price targets for LPTX or view top-rated stocks among Wall Street analysts.
- Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating.
- Since 1988 it has more than doubled the S&P 500 with an average gain of +24.32% per year.
- Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand.
- Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends.
- The monthly returns are then compounded to arrive at the annual return.
That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score.
The average twelve-month price prediction for Leap Therapeutics is $18.80 with a high price target of $30.00 and a low price target of $7.00. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, gynecologic cancers, or prostate cancer. Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer.
Leap Therapeutics’ stock is owned by many different retail and institutional investors. The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat’s FREE daily newsletter. /PRNewswire/ — If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this…
LPTX’s beta can be found in Trading Information at the top of this page. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Click the link below and we’ll send you MarketBeat’s list of seven best retirement stocks and why they should be in your portfolio.
Leap Therapeutics Announces Appointment of Richard L. Schilsky, MD to its Board of Directors
The company was founded on January 3, 2011 and is headquartered in Cambridge, MA. According to 4 analysts, the average rating for LPTX stock is “Strong Buy.” The 12-month stock price forecast is $16.38, which is an increase of 859.02% from the latest price. Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.
The consensus rating for Leap Therapeutics is Buy while the average consensus rating for medical companies is Moderate Buy. Sign-up to receive the latest news cirrus vision jet price in india and ratings for LPTX and its competitors with MarketBeat’s FREE daily newsletter. One share of LPTX stock can currently be purchased for approximately $1.65.
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer.
Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. Positive clinical trial results are giving investors a reason to cheer. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. 19.5 months median OS in the overall first-line patient population, exceeding current benchmarks Long-term follow-up identifies additional patient with partial response, resulting in 73% ORR in overal… The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries.
Leap Therapeutics Announces First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients
For example, a price above its moving average is generally considered an upward trend or a buy. High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.
The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. 55% ORR, 73% DCR, and 7.7 month PFS in DKK1-high/PD-L1-high second-line gastric cancer patients DKN-01 also demonstrated preclinical tumor regression data in CRC models supporting ongoing clinical tri… Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes.
Data may be intentionally delayed pursuant to supplier requirements. These two biotech stocks are set to report key clinical data later this year. As an investor, you want to buy stocks with the highest probability of success.
Median Progression-Free Survival of 11.3 months in first-line gastric cancer patients treated with DKN-01 plus tislelizumab and CAPOX, exceeding benchmarks in the overall population and in DKK1 and PD… Adds FL-301, clinical stage anti-Claudin18.2 antibody, and two preclinical antibody programs to Leap’s pipeline Combined cash balance of approximately $115 million enhances runway to mid-2025, fully-f… NEW YORK , Jan. 30, 2023 /PRNewswire/ — If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights…
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.32% per year. These returns cover a period from January 1, 1988 through July 31, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return.
Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts. The Barchart Technical Opinion widget shows you today’s overally Barchart Opinion with general information on how to interpret the short and longer term signals. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study.
LPTX Related stocks
According to analysts, Leap Therapeutics’s stock has a predicted upside of 419.90% based on their 12-month price targets. Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015.
The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. Compare
LPTX’s historical performance
against its industry peers and the overall market. Our Quantitative Research team models direct competitors or comparable companies
from a bottom-up perspective to find companies describing their business in a